NovoCure shares surged 39.3% following Q1 2026 earnings, as the launch of Optune Pax for pancreatic cancer surpassed investor expectations with rapid adoption, early prescription momentum, and a major payer coverage win.

• NovoCure’s U.S. launch of Optune Pax for locally advanced pancreatic cancer saw 169 prescriptions and 90 patient starts within the first seven weeks post-FDA approval; end-of-quarter backlog signals sustained demand.
• Elevance Health (covering 30 million lives) issued first major payer coverage policy for Optune Pax in the quarter, providing early validation for reimbursement.
• Active patient counts and net revenues both achieved double-digit year-over-year growth, with core GBM business growing 9% in active patients globally.
• Product enhancements, such as improved TTFields arrays and patient support tools, contributed to higher therapy persistence rates, increasing to 73% from below 70% in recent years.
• Clinical progress included PANOVA-4 trial results showing a 74% disease control rate with TTFields in metastatic pancreatic cancer and encouraging data supporting combinations with emerging targeted therapies.